^
AstraZeneca/Oxford say COVID-19 vaccine shows 70% efficacy
(FILES) In this file photo taken on November 17, 2020 An illustration picture shows vials with Covid-19 Vaccine stickers attached and syringes, with the logo of the University of Oxford and its partner British pharmaceutical company AstraZeneca. British drugs group AstraZeneca and the University of Oxford on November 23, 2020 said their jointly-developed vaccine against Covid-19 has shown "an average efficacy of 70 percent" in trials. The results ranged between 62 and 90 percent efficacy depending on the vaccine dosage.
AFP/Justin Tallis

AstraZeneca/Oxford say COVID-19 vaccine shows 70% efficacy

(Agence France-Presse) - November 23, 2020 - 5:28pm

LONDON, United Kingdom — British drugs group AstraZeneca and the University of Oxford on Monday said their jointly-developed vaccine against COVID-19 has shown "an average efficacy of 70%" in trials.

"This vaccine's efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency," AstraZeneca chief executive Pascal Soriot said in a statement.

The results ranged between 62 and 90% efficacy depending on the vaccine dosage.

The 70% average is lower compared with the efficacy of coronavirus vaccines trialed by rivals Pfizer/BioNTech and Moderna which have come in above 90%.

Monday's statement said "positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19... and no hospitalisations or severe cases of the disease were reported in participants." 

It added: "One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart."

The pair said that regimen n=8,895 showed 62% efficacy when given as two full doses at least one month apart. 

"The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%."

AstraZeneca said it would "immediately prepare regulatory submission of the data to authorities around the world that have a framework in place for conditional or early approval". 

It added that it would seek emergency-use listing from the World Health Organization to accelerate vaccine availability in low-income countries.

AstraZeneca said it is looking at a capacity of up to three billion doses of the vaccine in 2021 pending regulatory approval. 

It said the vaccine can be stored, transported and handled "at normal refrigerated conditions" of between two and eight degrees Celsius (36-46 degrees Fahrenheit) for at least six months.

'Save many lives'

More than 23,000 adults are currently being assessed in the trials, with the number expected to rise to up to 60,000, the statement said.

"Clinical trials are also being conducted in the US, Japan, Russia, South Africa, Kenya and Latin America with planned trials in other European and Asian countries," it added.

Oxford professor Andrew Pollard said the latest findings show "an effective vaccine that will save many lives". 

"Excitingly, we've found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply. 

"Today's announcement is only possible thanks to the many  volunteers in our trial, and the  hard working and talented team  of researchers based around the world," added Pollard, who is chief investigator of the Oxford Vaccine Trial.

ASTRAZENECA COVID-19 VACCINES NOVEL CORONAVIRUS OXFORD
As It Happens
LATEST UPDATE: June 20, 2021 - 3:19pm

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

June 20, 2021 - 3:19pm

China has now administered more than a billion doses of Covid vaccines, the country's health authority said Sunday, more than a third of the number given worldwide.

It comes after the number of doses administered globally surpassed 2.5 billion on Friday, according to an AFP count from official sources.

—  AFP

June 19, 2021 - 11:52am

The Palestinian Authority says it cancelled a swap deal that would have seen Israel provide it with one million COVID-19 jabs, as the doses were "about to expire".

Israeli officials earlier Friday had announced the deal, saying the Jewish state was to provide the doses to the Palestinian Authority as their expiry date loomed.

The PA, based in the occupied West Bank, had confirmed the delivery "in the coming days" of a million vaccine doses, without mentioning an agreement with the Jewish state. — AFP

June 17, 2021 - 3:16pm

Australia recommends that AstraZeneca's Covid-19 jab should not be given to people under 60 on Thursday, a fresh blow to the country's glacial vaccine rollout.

Health Minister Greg Hunt says concerns over possible links to blood clots meant Pfizer was now "the preferred vaccine" for everyone under 60 years old.

Australian authorities had already restricted the AstraZeneca shot to those over 50 in April, after several cases of severe blood clots were possibly linked to it. —  AFP

June 15, 2021 - 8:47pm

Covid vaccine-maker AstraZeneca reveals it had hit a setback in trials of a treatment for the coronavirus.

The drug, made from a combination of two antibodies, failed its main goal to treat COVID-19 symptoms in exposed patients, AstraZeneca says in a statement.

The treatment has been undergoing phase 3 or final clinical trials to assess its safety and efficacy. — AFP

June 12, 2021 - 1:42pm

The US Food and Drug Administration says it had told Johnson & Johnson that millions of doses of COVID-19 vaccine produced at a troubled plant can't be used because of possible contamination issues.

In a statement, the FDA says "several" batches of vaccine manufactured at the Emergent BioSolutions facility in the city of Baltimore are not suitable for use. Each batch is known to correspond to several million doses.

Neither the agency nor J&J revealed the precise number of doses, but The New York Times placed the number at 60 million, quoting people familiar with the matter. — AFP

Philstar
  • Latest
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with